According to a study published in the August 2 issue of Science, scientists have made an important move toward being able to perform three-dimensional bioprinting of functional organs after researchers have devised a way to reconstruct human heart components step.
Researchers at Carnegie Mellon University have developed an advanced version of the Freeform Reversible Embedding of Suspended Hydrogels (FRESH) technology, an unprecedented 3D printed collagen that builds parts of the human heart, from small blood vessels to valves to the ventricles. Beat. Recently obtained the US patent 10,150,258, FRESH technology has been licensed by FluidForm, and FluidForm is committed to greatly expanding the capabilities of 3D printing.
“We now have the ability to build constructs that reproduce key structural, mechanical and biological properties of native organizations,” said Professor Adam Feinberg, CTO and co-founder of FluidForm, Carnegie Mellon, Resident Biomaterials and Treatment Group. The place where the study was completed. “There are still many challenges that need to be overcome to get us into bioengineered 3D organs, but this research represents an important step forward.”
Although 3D bioprinting has achieved important milestones, direct printing of live cells and soft biomaterials has proven difficult. A key hurdle is the support of soft and dynamic biomaterials during the printing process to achieve the resolution and fidelity required to reconstruct complex 3D structures and functions.
FRESH uses an embedded printing method to solve this challenge by using a temporary support gel, which makes it possible to print complex scaffolds using native unmodified forms of collagen 3D. In the past, researchers were limited because soft materials were difficult to print with high fidelity of several layers due to sagging.
Led by the co-founder and FluidForm co-founders Andrew Lee and Andrew Hudson, nine members of the Carnegie Mellon team overcome these obstacles by developing a way to drive collagen self-assembly using rapid pH changes.
The FRESH 3D bioprinted heart is based on human MRI and accurately reproduces patient-specific anatomy. The smaller ventricles of the printed human cardiomyocytes showed synchronous contraction, directional action potential propagation, and wall thickening by 14% during the peak contraction. However, challenges remain, including the billions of cells needed to produce 3D printed larger tissues, the scale of manufacturing, and the undefined clinical translation monitoring process.
Although the human heart is used for proof of concept, FRESH printing of collagen and other soft biomaterials is a platform that is likely to build advanced scaffolds for various tissue and organ systems.
“FluidForm is very proud of the research at Feinberg Labs,” said FluidForm CEO Mike Graffeo. “The FRESH technology developed by Carnegie Mellon University enables bioprinters to achieve unprecedented structural, resolution and fidelity, thus enabling a huge leap in this field. We are very pleased to offer this to researchers around the world. Technology."
FluidForm commercializes FRESH technology through its first product LifeSupport(TM) bioprinting support gel, enabling researchers around the world to obtain efficient 3D bioprinting of collagen, cells and various biomaterials.